<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03039751</url>
  </required_header>
  <id_info>
    <org_study_id>KUH5101111</org_study_id>
    <nct_id>NCT03039751</nct_id>
  </id_info>
  <brief_title>Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris</brief_title>
  <acronym>ReGenHeart</acronym>
  <official_title>Clinical Development and Proof of Principle Testing of New Regenerative Adenovirus Vascular Endothelial Growth Factor (VEGF-D) Therapy for Cost-effective Treatment of Refractory Angina. A Phase II Randomized, Double-blinded, Placebo-controlled Study (ReGenHeart)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio Madrileño de Salud, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FinVector Vision Therapies Oy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Śląski Uniwersytet Medyczny w Katowicach</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Euram Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kuopio University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and efficacy of catheter mediated&#xD;
      endocardial adenovirus-mediated vascular endothelial growth factor-D (AdVEGF-D) regenerative&#xD;
      gene transfer in patients with refractory angina to whom revascularisation cannot be&#xD;
      performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study overview:&#xD;
&#xD;
      The purpose of the study is to evaluate the safety and efficacy of catheter mediated AdVEGF-D&#xD;
      regenerative gene transfer in patients with refractory angina to whom revascularisation&#xD;
      cannot be performed.&#xD;
&#xD;
      Primary objectives:&#xD;
&#xD;
      To test the efficacy of the therapy to improve functional capacity using 6 minute walking&#xD;
      test after 6 months follow-up and improvement of symptoms assessed by Canadian Cardiovascular&#xD;
      Society (CCS) class.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      Efficacy of the gene transfer to increase to improve functional capacity using 6 minute&#xD;
      walking test and improvement of symptoms assessed by CCS class after 12 months as well as&#xD;
      increase in myocardial perfusion assessed 6 months after the gene transfer. In addition, at 6&#xD;
      and 12 months timepoints, the improvement quality of life (QoL), the use of angina pectoris&#xD;
      medication, major adverse cardiac events related to coronary artery disease (cardiovascular&#xD;
      death, myocardial infarction, stroke, revascularization and hospital admission due to&#xD;
      coronary artery disease) or a combined endpoint of the above (Major Adverse Cardiac Events,&#xD;
      MACE) will be evaluated.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      ReGenHeart is a randomized, double-blinded, placebo-controlled multicentre phase II study&#xD;
      which will be conducted at 6 centers. The study will evaluate the efficacy and safety of&#xD;
      catheter mediated endocardial AdVEGF-D regenerative gene transfer in 180 patients with angina&#xD;
      pectoris or equivalent symptom despite optimal medical therapy and who are not suitable&#xD;
      candidates for coronary revascularization with coronary artery bypass grafting (CABG) or&#xD;
      percutaneous coronary intervention (PCI) (refractory angina patients).&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      180 patients will be recruited from the six centers in 2 years. The patients will be selected&#xD;
      for the trial on the basis of medical history, general status, laboratory analyses, coronary&#xD;
      angiogram and 6-minute walking test. Patients with CCS 2-3 angina pectoris despite optimal&#xD;
      medical therapy and who are not eligible for coronary angioplasty or bypass operation due to&#xD;
      diffuse coronary stenosis, small coronary vessels, repeated revascularization or too high&#xD;
      risk for operation, will be included.&#xD;
&#xD;
      The number of subjects to be recruited and randomized to the trial will be 180 (2:1 ratio to&#xD;
      the treatment and control groups).&#xD;
&#xD;
      Investigational drug product:&#xD;
&#xD;
      First generation replication-deficient AdVEGF-D produced in 293 cells will be injected into&#xD;
      ten sites in the endocardium. The dose of 1x1011 vp in a total volume of 2 ml (10 times 0.2&#xD;
      ml) will be used. Control patients will be treated and operated exactly in the same way&#xD;
      except that placebo (buffer solution without gene) injection into the myocardium is used.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functional capacity at 6 months</measure>
    <time_frame>6 months after gene transfer</time_frame>
    <description>Improvement of exercise capacity 6 months after the treatment as measured by 6 minute walking test (walking distance in meters)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of angina pectoris symptoms at 6 months</measure>
    <time_frame>6 months after gene transfer</time_frame>
    <description>Relieve of angina symptoms 6 months after the treatment (CCS class)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional capacity at 12 months</measure>
    <time_frame>12 months after gene transfer</time_frame>
    <description>Improvement of exercise capacity 12 months after the treatment as measured by a 6 minute walking test (walking distance in meters)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of angina pectoris symptoms at 12 months</measure>
    <time_frame>Time Frame: 12 months after gene transfer</time_frame>
    <description>Relieve of angina symptoms 12 months after the treatment (CCS class)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial perfusion at 6 months</measure>
    <time_frame>6 months after gene transfer</time_frame>
    <description>Improvement of myocardial perfusion (myocardial perfusion reserve, MPR) at 6 months assessed with positron emission tomography (PET) or single-photon emission computed tomography (SPECT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (EQ-5) at 6 and 12 months</measure>
    <time_frame>6 and 12 months after gene transfer</time_frame>
    <description>Improvement of QoL assessed with EQ-5 score with three levels of severity and visual analogue scale (VAS) at 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Short-Form Health Survey) at 6 and 12 months</measure>
    <time_frame>6 and 12 months after gene transfer</time_frame>
    <description>Improvement of QoL assessed with Short-Form Health Survey (SF-36) score at 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (Seattle Angina Questionnaire ) at 6 and 12 months</measure>
    <time_frame>6 and 12 months after gene transfer</time_frame>
    <description>Improvement of QoL assessed with Seattle Angina Questionnaire score at 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina pectoris medication at 6 and 12 months</measure>
    <time_frame>6 and 12 months after gene transfer</time_frame>
    <description>Use of short-acting nitrates to relieve symptoms of angina pectoris at 6 and 12 months (number of oral/sublingual nitrate tablets or nitrate spray inhalations during the preceding 4 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse cardiac events at 6 and 12 months</measure>
    <time_frame>6 and 12 months after gene transfer</time_frame>
    <description>Incidence of cardiovascular death, myocardial infarction, stroke, revascularization or hospital admission due to coronary artery disease and a combined endpoint of Major Adverse Cardiac Events MACE (combined endpoint of cardiovascular death, myocardial infarction, stroke, revascularization or hospital admission due to coronary artery disease) at 6 and 12 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Refractory Angina Pectoris</condition>
  <condition>Gene Transfer</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>AdvVEGF-D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramyocardial AdVEGF-D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramyocardial placebo (buffer solution without gene)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AdvVEGF-D</intervention_name>
    <description>AdvVEGF-D will be injected into 10 sites of the myocardium</description>
    <arm_group_label>AdvVEGF-D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control Rx</intervention_name>
    <description>Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  informed consent signed&#xD;
&#xD;
          -  age &gt; 30 but &lt; 85 years&#xD;
&#xD;
          -  significant angina pectoris (CCS 2-3) despite of optimal medication&#xD;
&#xD;
          -  significant stenosis (&gt; 60%) in coronary angiography (&lt; 6 months)&#xD;
&#xD;
          -  contraindication to CABG or PCI due to diffuse or distal stenosis, chronic total&#xD;
             occlusion, vessels with difficult anatomy, stenosis with severe calcifications and&#xD;
             stenosis in small vessels (&lt;2.5 mm))&#xD;
&#xD;
          -  angina pectoris or equivalent symptoms in the 6-minute walking exercise test&#xD;
&#xD;
          -  left ventricle wall &gt; 8 mm detected by transthoracic echocardiography or magnetic&#xD;
             resonance imaging (treatment area)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  women in fertile age&#xD;
&#xD;
          -  diabetes mellitus with severe complications such as diabetic retinopathy or&#xD;
             nephropathy&#xD;
&#xD;
          -  clinically significant anemia (hemoglobin count &lt; 120 mg/l in male, &lt; 110 mg/l in&#xD;
             female; hematocrit &lt; 0.36), leukopenia (b-leukocyte count &lt; 3.0x109/l), leukocytosis&#xD;
             (b-leukocyte count &gt; 12.0x109/l) or thrombocytopenia (b-thrombocyte count &lt; 100x109/l)&#xD;
&#xD;
          -  renal insufficiency (P-creatinine &gt; 160 mg/l)&#xD;
&#xD;
          -  liver insufficiency (P-alanine aminotransferase or P-alkaline phosphatase over 2 x&#xD;
             normal)&#xD;
&#xD;
          -  haematuria of unknown origin&#xD;
&#xD;
          -  severe hypertension (systolic blood pressure &gt; 200 mmHg or diastolic blood pressure &gt;&#xD;
             110 mmHg) or significant hypotension (systolic blood pressure &lt; 90 mmHg)&#xD;
&#xD;
          -  significant obesity (Body Mass Index &gt; 35)&#xD;
&#xD;
          -  acute infection&#xD;
&#xD;
          -  immunosuppressive medication&#xD;
&#xD;
          -  significant impairment of left ventricular function (ejection fraction &lt; 25% in&#xD;
             echocardiography)&#xD;
&#xD;
          -  symptomatic congestive heart failure (New York Heart Association class 3-4)&#xD;
&#xD;
          -  haemodynamically significant (grade 3-4/4) aortic or mitral regurgitation or other&#xD;
             heart disease needing surgery&#xD;
&#xD;
          -  recent (&lt; 6 weeks) acute coronary syndrome or myocardial infarction, PCI or CABG,&#xD;
             stroke or transient ischemic attack (TIA)&#xD;
&#xD;
          -  current or suspected malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seppo Ylä-Herttuala</last_name>
    <role>Study Director</role>
    <affiliation>Kuopio University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juha EK Hartikainen, professor</last_name>
    <phone>+358447113945</phone>
    <email>juha.hartikainen@kuh.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seppo Ylä-Herttuala, professor</last_name>
    <phone>+358505924067</phone>
    <email>seppo.ylaherttuala@uef.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Kastrup, professor</last_name>
      <email>jens.kastrup@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juha Hartikainen, professor</last_name>
      <email>juha.hartikainen@kuh.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2017</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data wil be shared to Partners of ReGenHeart Consortium</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

